Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis

Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis

Nasal delivery of large peptides such as parathyroid 1-34 (PTH 1-34) can benefit from a permeation enhancer to promote absorption across the nasal mucosa into the bloodstream. Previously, we have published an encouraging bioavailability (78%), relative to subcutaneous injection in a small animal pre...

Full description

Bibliographic Details
Main Authors: Richard G. Pearson, Tahir Masud, Elaine Blackshaw, Andrew Naylor, Michael Hinchcliffe, Kirk Jeffery, Faron Jordan, Anjumn Shabir-Ahmed, Gareth King, Andrew L. Lewis, Lisbeth Illum, Alan C. Perkins
Format: Article
Language:English
Published: MDPI AG 2019-06-01
Series:Pharmaceutics
Subjects:
PTH 1-34
teriparatide
nasal delivery
pharmacokinetics
osteoporosis
man
sheep
clinical trial
preclinical
Online Access:https://www.mdpi.com/1999-4923/11/6/265

Similar Items

Similar Items